Literature DB >> 11480454

Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.

S Morikawa1, M Umetani, S Nakagawa, H Yamazaki, H Suganami, K Inoue, M Kitahara, T Hamakubo, T Kodama, Y Saito.   

Abstract

The effect of various 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on the induction of HMG-CoA reductase and low density lipoprotein (LDL) receptor mRNA were quantitatively determined in the cultured human hepatoma cell line Hep G2 by means of a ribonuclease protection assay. Lipophilic inhibitors including mevastatin, simvastatin, atorvastatin and NK-104 were able to increase the levels of mRNAs for HMG-CoA reductase and the LDL receptor, but the hydrophilic inhibitor pravastatin was not effective in Hep G2 cells as had previously been reported. The LDL receptor mRNA was induced by NK-104 most effectively between 0.1 to 10 microM among the lipophilic inhibitors, whereas the degrees of induction of HMG-CoA reductase mRNA by these inhibitors did not differ significantly from each other. When cells were treated with a 200-fold excess of the IC50 concentration of each inhibitor, NK-104 was able to induce LDL receptor mRNA most effectively. These results indicate that the effect of HMG-CoA reductase inhibitors on the upregulation of mRNA for reductase and LDL receptor are different from each other and among these lipophilic inhibitors. NK-104 is most effective in inducing LDL receptor mRNA in Hep G2 cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11480454     DOI: 10.5551/jat1994.7.138

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  15 in total

1.  Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects.

Authors:  Hirotaka Nagashima; Masahiro Endo
Journal:  Heart Vessels       Date:  2010-12-04       Impact factor: 2.037

Review 2.  Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

3.  Pitavastatin: finding its place in therapy.

Authors:  Leiv Ose
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

Review 4.  Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals.

Authors:  Yasushi Saito
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

Review 5.  Fluvastatin: clinical and safety profile.

Authors:  Alberto Corsini; Terry A Jacobson; Christie M Ballantyne
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus.

Authors:  Yasuyuki Kawai; Ryoko Sato-Ishida; Atsushi Motoyama; Kouji Kajinami
Journal:  Drug Des Devel Ther       Date:  2011-05-11       Impact factor: 4.162

7.  Pitavastatin: evidence for its place in treatment of hypercholesterolemia.

Authors:  Peter Alagona
Journal:  Core Evid       Date:  2010-10-22

Review 8.  Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients.

Authors:  Kevin W Chamberlin; William L Baker
Journal:  Clin Interv Aging       Date:  2015-04-16       Impact factor: 4.458

Review 9.  Pitavastatin in cardiometabolic disease: therapeutic profile.

Authors:  Luis Masana
Journal:  Cardiovasc Diabetol       Date:  2013-05-30       Impact factor: 9.951

10.  Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).

Authors:  Ping-Yen Liu; Liang-Yu Lin; Hung-Ju Lin; Chien-Hsun Hsia; Yi-Ren Hung; Hung-I Yeh; Tao-Cheng Wu; Ju-Yi Chen; Kuo-Liong Chien; Jaw-Wen Chen
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.